Rare canine case links chylopericardium, thrombosis, and mesothelioma

A case report in Veterinary Sciences is putting a spotlight on one of the rarer combinations in small animal cardiothoracic medicine: chylopericardium in a dog with concurrent chylothorax, mesothelioma, and bilateral brachiocephalic vein thrombosis. The patient, a 6-year-old neutered male Shiba Inu, presented with respiratory distress and was diagnosed with both pleural and pericardial chylous effusions, with CT reportedly showing multiple thoracic ducts and thrombosis affecting both brachiocephalic veins. The case stands out because chylopericardium itself is uncommon in dogs, and published veterinary literature on its mechanisms and optimal treatment remains limited. (pmc.ncbi.nlm.nih.gov)

That rarity is part of the story. Earlier canine reports have described isolated chylopericardium, chylopericardium that later progressed to chylothorax, and cases tied to venous obstruction or catheter-associated thrombosis. One 2006 JAVMA case was described as the first report of chylopericardium developing before chylothorax in a dog, while later reports connected chylous effusions to cranial vena caval obstruction, pacemaker-associated thrombosis, or jugular venous thrombosis in dogs receiving long-term hemodialysis. Taken together, those reports have gradually shifted the conversation away from a purely idiopathic model and toward a broader differential list that includes impaired lymphatic drainage from central venous disease. (pubmed.ncbi.nlm.nih.gov)

That context helps explain why the new report matters. In dogs, chylothorax has been associated with central venous thrombosis and obstruction before, including lesions involving the cranial vena cava and brachiocephalic veins. Human case literature has also described concurrent chylothorax and chylopericardium as a consequence of central venous thrombosis or stenosis, reinforcing the biologic plausibility of the mechanism proposed in this canine case. The combination of bilateral brachiocephalic vein thrombosis with mesothelioma raises the possibility that more than one process may have been contributing to lymphatic outflow failure in this patient. That’s an inference from the surrounding literature, but it’s a clinically useful one. (pmc.ncbi.nlm.nih.gov)

Mesothelioma is another important piece. Pericardial mesothelioma in dogs is uncommon, but it’s a recognized cause of pericardial effusion and can be diagnostically frustrating. Published pathology reviews note that distinguishing neoplastic from reactive mesothelial proliferations is difficult, particularly when biopsy samples are small or inflammation is present. Other canine case reports have linked pericardial mesothelioma with chylothorax, and retrospective work has shown that mesothelioma-related pericardial effusion can mimic more benign pericardial disease early in the course. (pmc.ncbi.nlm.nih.gov)

There doesn’t appear to be a broad wave of published expert commentary on this specific report yet, which isn’t unusual for a single veterinary case report. But recent peer-reviewed discussion in Frontiers in Veterinary Science has emphasized that chylopericardium remains rare in veterinary medicine and that venous thrombosis should be considered a plausible secondary cause, particularly when indwelling devices, stenosis, or obstructive lesions are present. That aligns with the clinical takeaway from this case: if a dog has recurrent chylous effusions in more than one thoracic compartment, clinicians may need to think beyond standard idiopathic chylothorax algorithms. (frontiersin.org)

Why it matters: For veterinary professionals, this report reinforces the value of a layered diagnostic approach. Dogs with recurrent chylothorax are often worked up for idiopathic disease, thoracic duct abnormalities, or surgical candidacy, but this case argues for equal attention to the venous side of the equation and to occult neoplasia. Advanced imaging may be especially important when pleural and pericardial chylous effusions occur together, because venous obstruction, collateral formation, thoracic duct abnormalities, and pericardial disease may all be in play at the same time. That has implications for internists, cardiologists, surgeons, radiologists, and pathologists trying to decide whether drainage alone, thoracic duct surgery, pericardiectomy, anticoagulation, biopsy, or palliation is the most rational next step. (pubmed.ncbi.nlm.nih.gov)

The case also lands at a moment when the profession is paying closer attention to the downstream effects of venous obstruction. Reports involving pacemaker leads, dialysis catheters, and other central venous insults have already shown that thrombosis can reshape thoracic lymphatic drainage in dogs. This new case extends that idea into a more complicated oncology setting, where thrombosis and neoplasia may intersect rather than compete as explanations. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is whether additional case series or referral-center reviews can clarify how often central venous thrombosis and mesothelioma are missed contributors in dogs labeled with idiopathic chylous effusions, and whether that changes imaging protocols or treatment selection. (pmc.ncbi.nlm.nih.gov)